A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Trial Profile

A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs SD 101 Dynavax (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Dynavax Technologies
  • Most Recent Events

    • 02 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Interim results (n=13, data cut off: Aug 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Dec 2016 According to a Dynavax media release, data from this trial (n=28) were presented at the 58th American Society of Hematology (ASH) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top